APPENDIX A

 

Research Listing

 

Much research was presented during the 1998 trial of Dr. Sinaiko.  More research was offered at the Reconsideration Hearing.  Even more research is currently available.

 

All of this research has been ignored by the Medical Board Prosecutor.

 

As is known, it may take years before a researcher actually publishes his research study, so that a newly published study may be well known by people in the field through seminars and personal contact for upwards of a decade prior to publication.

 

Attached is a listing of the research on EPD because the so-called State Experts insisted that there was no research and that they could not find anything on a search of MedLine.  While some of these experts did a search of “EPD” or “E.P.D.” and claimed to find “nothing,” we who are not doctors did a similar search and found quite few studies.  Every single study makes EPD sound like the best thing since sliced bread.  Not one – not one – study indicates that EPD is either harmful or useless. 

 

We who are not doctors further wonder how a doctor appointed by the Medical Board becomes an “expert” on a subject such as EPD based on reading only the abstracts of any studies anyway, yet some “expert” opinions were based on nothing more than this, and others not even on this much, but rather on the opinion that if it were any good, he would have already heard of it.

(TR Vol. 13, p. 60) Dr. Zlotlow, State expert, says, about EPD:

 

. . . The conclusion I

          

       5   reached is that I have never seen, read or heard of that

          

       6   particular material being used in the treatment of human

          

       7   disease prior to receiving the data that I reported on,

 

 

(TR Vol. 12, p. 43) Dr. Tepper, a psychiatrist, who can be forgiven for knowing nothing about the allergy treatment EPD, but who cannot be forgiven for acting the part of an “expert” here:

 

   22           Q. (Terrazas) Would you, please, describe the nature

 

         23   and the extent of any experience or research that

 

         24   you've done?

 

         25           A.     I hadn't heard of it until I reviewed

 

         26   this case, and then I did a med-line search, a multiple

 

         27   med-line search, trying to find information on it.

 

Poor Dr. Tepper found ONE article on EPD in MedLine after all his searching, and this made him into the expert he is today.

 

Based on the testimony manufactured and brought forth by Mr. Terrazas, by redefining “compounding” as “adulteration” and brushing aside the training allergists have in the com-pounding of specialty allergy treatments for individual patients, and redefining that as “using unproven treatments and unproven drugs,” the FDA – opposing their own representative’s testimony that the enzyme beta glucuronidase did not need FDA approval or oversight and was not a “drug” – has now insisted on a New Investigational Drug application for beta glucuroni-dase and has stopped all use of EPD on new patients.  Patients are suffering because EPD availability is now heading toward nonexistence.  People who need this treatment simply cannot get it – because of the precedent set by this case, thanks to Mr. Terrazas’ leadership in re-writing history and science. 

 

The precedent, in a nutshell, is that those who have never used a treatment and have no knowledge of it shall be the ones to decide if anyone else can use it.  Is this what we want?

 

A listing of all studies found on EPD and some on antifungal treatment use in allergy is attached.  A partial research listing of studies on the effect of diet on behavior, on allergy, and on skin problems such as the boy’s seasonal eczema, can be found at www.diet-studies.com/adhd.html

and www.diet-studies.com/skin.html

 

Listings and full texts of these studies, of studies on MCS (chemical sensitivity) and research on antifungal treatments and allergy are available upon request. 


 

Research on EPD and Antifungal Treatment in Allergy

 

www.dma.org/~rohrers/allergy/epd_faq.htm

www.treatmentchoice.org/pimup_1-1.html

 

  1. Angelini G. Curatoli G. D’Argento V. Vena GA. (in press). Pollinosi: una nuova metodica di immunoterapia.

 

  1. Astarita C, Scala G, Sproviero S, Franzese A. 1996. Effects of enzyme potentiated desensitisation in the treatment of pollinosis: A double-blind placebo-controlled trial. J. Invest. Allergol. Clin. Immunol.; 6:248-255.

 

  1. Cantani A, Ragno V, Monteleone M, Lucenti P, Businco L. 1996. Enzyme potentiated desensitisation in children with asthma and mite allergy: A double-blind study. J. Invest. Allergol. Clin. Immunol. 6: 270-276.

 

  1. Caramia G, Franceschini F, Cimarelli ZA, Ciucchi MS, Gagliardini R, Ruffini E. 1996. The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children. Allergie et Immunologie 28, 308-10.

 

  1. Di Stanislao C. Mazzocchetti E. Bologna G Chimenti S. EPD secondo McEwen: Studio cliniico, istologia e immunoistochimico. Bollentino de dermatologia allergologia e professionale, 2, 1994

 

  1. Di Stanislao C, Di Berardino L, Bianchi I, Bologna G. 1997.  A double-blind, placebo-controlled study of preventive immunotherapy with E.P.D., in the treatment of seasonal allergic disease.  Allerg Immunol (Paris) 1997 Feb;29(2):39-42

 

  1. Eaton KK, Howard M, Howard JM. 1995. Gut permeability measured by polyethylene glycol absorption in abnormal gut fermentation as compared with food intolerance. J R Soc Med 1995 Feb;88(2):63-6.

 

  1. Eaton KK. 1991. Preliminary studies with enzyme potentiated desensitization in canine atopic dermatitis.  Environmental Medicine. 8:140-1.

 

  1. Egger, J. et al. 1992. Enzyme Potentiated Desensitization, a proven treatment for food-induced hyperactivity.  The Lancet, 9 May, 1992.

 

  1. Egger J, Stolla A, McEwen LM. 1992. Controlled trial of hyposensitisation in children with food-induced hyperkinetic syndrome. The Lancet 339: 1150-1153.

 

  1. Egger J, Stolla A, McEwen LM. Hyposensibilisierung bei nahrungsmittelinduzierter Migrane. Aktuelle Neuropadiatrie 1992. Lischka A, Bernett G (Eds.) 1992 pp.287-291. Ciba-Geigy Verlag, Wehr 1993.

 

  1. Egger J, Stolla A, McEwen LM. 1993. Controlled trial of hyposensitisation in children with food induced migraine. Cephalalgia 13 (Suppl. 13), 216.

 

  1. Fell P, Brostoff J. 1990. A single-dose desensitisation for summer hay fever. Results of a double-blind study - 1988. Eur. J. Clin. Pharmacol. 38: 77-79.

 

  1. Galland L. McEwen L.M. 1996. A role for food intolerance in childhood migraine. World Ped. & Child Care.  6: 2-8.

 

  1. Ippoliti F, Rivi R, Businco L. Effect of preseasonal enzyme potentiated desensitisation (EPD) on plasma-IL-6  and IL-10 of grass pollen-sensitive asthmatic children. Allerg Immunol (Paris) 1997 May;29(5):120

 

  1. Kroker, G.F., 1987. Chronic Candidiasis and Allergy in Food Allergy and Intolerance (First Edition). Brostoff, J., Challacombe, S. (eds.) London: Bailliere Tindall. pp. 850-870, Chapter 49

 

  1. Longo G, Poli F, Bertoli G. 1992. Efficacia clinica di un nuovo trattamento iposensibilizzante, EPD (enzyme potentiated desensitisation) nella terapia della pollinosi. Riforma Med. 107: 171-176.

 

  1. McEwen, L.M., May, 1997. Allergy and EPD, pp. A11-22. (EPD Manual: Use of antifungals as an essential part of EPD)

 

  1. McEwen LM. Hyposensitization. In: Brostoff J and Challacombe SJ., Eds. Food allergy and intolerance.  London; Bailliere Tindall, 985-94, 1987.

 

  1. McEwen LM. 1987. A double-blind controlled trial of enzyme potentiated hyposensitization for the treatment of ulcerative colitis. Clinical Ecology. 5(2):47-51, 1987.

 

  1. McEwen LM. Nicholson M. Kitchen I. O’Gorman J. White S. 1975. Enzyme potentiated hyposensitization IV:  Effect of protamine on the immunological behavior of beta-glucuronidase in mice and patients with hay fever.  Annals of Allergy. 34:290-5.

 

  1. McEwen LM. 1975. Enzyme potentiated hyposensitization V: Five case reports of patients with acute food allergy. Annals of Allergy. 35:98-103.

 

  1. McEwen LM. Nicholson M. Kitchen I. White S. 1973. Enzyme potentiated hyposensitization III: Control by sugars and diols of the immunological effect of beta-glucuronidase in mice and patients with hay fever. Annals of Allergy. 34:290-5.

 

  1. McEwen LM. 1973. Enzyme potentiated hyposensitization II: Effect of glucose, glucosamine, N-acetylamino-sugars and gelatin on the ability of beta-glucuronidase to block the anamnestic response to antigen in mice. Annals of Allergy. 31:79-83,1973.

 

  1. McEwen LM. 1973, April. Effects of sugars and diols on enzyme potentiated desensitization. Journal of Physiology. 230(1): 65-6.

 

  1. McEwen LM. Starr MS. 1972. Enzyme potentiated hyposensitization I: The effect of pre-treatment with beta-glucuronidase, hyaluronidase and antigen on anaphylactic sensitivity of guinea pigs, rats and mice. International Archives of Allergy. 42:152-8.

 

  1. McEwen LM. Ganderton MA. Wilson CW. Black JH. 1967. Hyaluronidase in the treatment of allergy. British Medical Journal. ii: 507-8.

 

  1. Pulec JL. Enzyme-potentiated desensitization: a major breakthrough [editorial].  Ear, Nose, & Throat Journal. 75(10): 640, 1996 Oct.

 

  1. Shrader Jr. WA. McEwen LM. 1993. Enzyme potentiated desensitization: A sixteen month trial of therapy with 134 patients. Environmental Medicine. 9 (3&4): 128-38.

 

  1. Shrader, Jr. WA.  The use of bacterial antigen EPD immunotherapy for the treatment of rheumatoid arthritis, reactive arthritis: the role of molecular mimicry (unpublished)

 

  1. Troise C et al, 2000.  Preventive symptomatic immunotherapy versus placebo in seasonal rhinitis due to grasses in children and to Parietaria in adult patients. Allerg Immunol (Paris) 2000 Jun;32(6):246-9

 

  1. Ward WA. Enzyme potentiated desensitization (EPD): a potential revolution in allergy care. Current Opinion in Otolaryngology & Head and Neck Surgery. 8:273-6, 2000.

 

Text Box: Note: The use of antifungals for chronic fatigue syndrome was advocated at a UCSF conference on chronic fatigue, held in San Francisco on 4/15/89.